{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"}],"units":"Participants"}],"description":"Progression-free survival (PFS) of the combination of RO4929097 with and without GDC-0449 in patients with advanced sarcoma. (Phase II)","groups":[{"description":"Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.\n\nGamma-Secretase Inhibitor RO4929097: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Arm I (Gamma-secretase Inhibitor RO4929097)"},{"description":"Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.\n\nGamma-Secretase Inhibitor RO4929097: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nVismodegib: Given PO","id":"OG001","title":"Arm II (Vismodegib and Gamma-secretase Inhibitor RO4929097)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 weeks","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}